What vet teams should know about compounding with Wedgewood
Bottom line
A new episode of The Veterinary Viewfinder puts a practical spotlight on veterinary compounding, featuring Wedgewood Pharmacy in a conversation about how compounded medications fit into everyday practice. The discussion comes as Wedgewood continues to expand its footprint in animal health, including a larger pharmacy network, an FDA-registered 503B outsourcing facility, and the Blue Rabbit online pharmacy platform. Wedgewood says it now serves more than 70,000 veterinarians and compounds from a formulary of more than 46,000 medications, underscoring how central large-scale compounding partners have become for many clinics. (wedgewood.com)
Why it matters: For veterinary professionals, compounding remains essential when no approved product meets a patient’s needs for strength, dosage form, flavoring, or species-specific administration. But it also sits inside a tightly watched regulatory framework: FDA says compounded animal drugs are generally not FDA-approved, and animal drug compounding from bulk drug substances is governed by agency guidance and enforcement discretion, while day-to-day oversight often falls to state boards of pharmacy. That makes pharmacy selection, quality systems, documentation, and client communication especially important when practices work with a high-volume partner like Wedgewood, which highlights PCAB accreditation, FDA-registered sourcing, and investment in expanded pharmacy capacity. (fda.gov)
What to watch: Expect continued attention on compounding quality, turnaround times, and home-delivery integration as Wedgewood’s Arizona expansion and Blue Rabbit platform mature. (wedgewood.com)
Key facts
- Topic
- Veterinary compounding
- Featured company
- Wedgewood Pharmacy
- Company claim
- Largest U.S. veterinary compounding pharmacy
- Veterinarians served
- More than 70,000
- Animals served each year
- One million
- Formulary size
- More than 46,000 medications
- FDA status
- Compounded animal drugs are generally not FDA-approved
- FDA guidance
- Guidance for Industry #256 on compounding from bulk drug substances
- New facility
- 90,000-square-foot veterinary pharmacy in Chandler, Arizona
A podcast episode may not sound like hard news, but The Veterinary Viewfinder’s discussion with Wedgewood Pharmacy lands at a moment when compounding is becoming even more embedded in veterinary workflow. Wedgewood has grown into the largest U.S. veterinary compounding pharmacy, according to the company, and its scale now stretches beyond custom medications into online pharmacy fulfillment and broader practice support. (wedgewood.com)
That context matters because veterinary compounding has long filled gaps that approved products can’t always solve. FDA describes animal drug compounding as a way to tailor medications for an individual animal or small group, but it also emphasizes that compounded animal drugs are typically not FDA-approved and have not gone through the same premarket review for safety, effectiveness, manufacturing, labeling, and packaging. The agency’s current framework, including Guidance for Industry #256 on compounding from bulk drug substances, has shaped how veterinarians and pharmacies navigate patient-specific needs while staying inside compliance expectations. (fda.gov)
Wedgewood’s recent corporate moves help explain why the company is showing up more often in conversations about practice operations. The company says it serves more than 70,000 veterinarians and one million animals each year, and has expanded through acquisitions including Diamondback Drugs, Wildlife Pharmaceuticals, ZooPharm, Front Range Laboratories, Brava Pharmacy, Wickliffe Pharmacy, and Precision Equine Pharmacy. It also launched Wedgewood Connect, an FDA-registered 503B outsourcing facility, and merged with Blue Rabbit to offer a PIMS-integrated online pharmacy platform for compounded and commercial medications, diets, and preventatives. (wedgewood.com)
The infrastructure buildout is continuing. In February 2024, Wedgewood broke ground on a 90,000-square-foot veterinary pharmacy in Chandler, Arizona, a facility the company said would open in early 2025 and eventually replace its smaller Arizona site. Wedgewood framed that investment as a way to improve delivery speed in the western U.S. and add local pickup options for pet parents, while also supporting growing demand for compounded medications. The company’s quality materials also emphasize PCAB accreditation, use of FDA-registered manufacturers for active pharmaceutical ingredients, and adherence to standards influenced by FDA, USP, and DEA requirements. (wedgewood.com)
Independent expert reaction tied specifically to this podcast episode was limited, but the broader professional view is clear: compounding is valuable, and oversight matters. AVMA has previously highlighted the need for veterinary involvement in compounding standards and has published guidance reminding clinicians that compounded preparations should be used in compliance with federal law and FDA policy. FDA, for its part, notes that it generally relies on state boards of pharmacy for routine oversight of pharmacy practice, while maintaining a federal role in enforcement and policy around compounded animal drugs. (avma.org)
Why it matters: For veterinary teams, the practical takeaway isn’t just that compounding is available, it’s that pharmacy choice is now a clinical and operational decision. Clinics increasingly need partners that can provide species-appropriate formulations, reliable turnaround, transparent quality controls, and clean workflows for prescribing and home delivery. At the same time, teams should remember the regulatory distinction between compounded and FDA-approved products, document the medical rationale for compounded use where appropriate, and set clear expectations with pet parents about what compounded drugs are, and are not. (fda.gov)
For practices already using Wedgewood, the company’s scale may translate into broader formulary access and better logistics. But scale can also raise the stakes for consistency, communication, and service recovery when delays or shortages happen. That’s one reason Wedgewood’s investments in new facilities, integrations, and fulfillment tools are worth watching beyond the pharmacy category itself, because they increasingly touch the full client experience. (wedgewood.com)
What to watch: The next signal will be whether Wedgewood’s expanded pharmacy capacity and Blue Rabbit integrations materially improve turnaround, delivery reach, and prescribing convenience for clinics, while FDA’s compounding oversight framework continues to shape how veterinary practices balance customization with compliance. (wedgewood.com)